Publications by authors named "Alexander D Carlin"
Combining two advanced therapies may improve outcomes in Crohn's disease (CD) refractory to monotherapy. We conducted a descriptive case series of 27 patients with CD who initiated combination therapy with upadacitinib and infliximab (n = 1), risankizumab (n = 17), ustekinumab (n = 3) or vedolizumab (n = 6). At 12 weeks, 24 achieved clinical response and 9 achieved steroid-free remission.
View Article and Find Full Text PDFArticle Synopsis
- Several anticancer drugs increase reactive oxygen species (ROS) levels to induce cell death, but the mechanisms of how ROS affects proteins linked to drug sensitivity and resistance are not well understood.* -
- Through a study of 11 anticancer drugs, researchers identified unique and common protein targets, including those in ribosomal components, highlighting shared mechanisms related to drug effects on protein translation.* -
- The study focuses on CHK1, which acts as a sensor for nuclear HO levels, preventing mitochondrial localization of SSBP1 and thereby reducing nuclear HO, indicating a pathway that could be targeted for improving resistance to platinum-based cancer treatments.*
Article Synopsis
- Chemotherapies may induce cell death by elevating levels of reactive oxygen species (ROS), but the specific mechanisms and proteins involved are not fully understood.* -
- Researchers investigated 11 different chemotherapies and discovered both unique and common protein targets, such as ribosomal components, highlighting a potential method through which these drugs affect protein translation.* -
- The study centered on the protein CHK1, which plays a role in sensing nuclear hydrogen peroxide (H2O2) and regulates mitochondrial function, revealing a pathway that can help cancer cells resist platinum-based chemotherapy in ovarian cancers.*